[{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"||Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase III","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Thomas Jefferson University \/ Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Lantheus Medical Imaging | Rothman Institute","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute","highestDevelopmentStatusID":"9","companyTruncated":"Thomas Jefferson University \/ Lantheus Medical Imaging | Rothman Institute"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Terry Fox Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Terry Fox Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute"}]

Find Clinical Drug Pipeline Developments & Deals for Definity

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 29, 2023

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Terry Fox Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Thomas Jefferson University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Thomas Jefferson University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2023

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Amsterdam UMC, VUmc | Futian People's Hospital | Eigen | GE Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Albutein® (albumin-human injection) is an abundant protein in plasma which has antioxidant and anti-inflammatory properties, and is being investigated for the treatment of decompensated Cirrhosis.

                          Product Name : Albutein

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 18, 2023

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 17, 2022

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Terry Fox Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Thomas Jefferson University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Thomas Jefferson University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 21, 2022

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Lantheus Medical Imaging | Rothman Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

                          Product Name : Albutein

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2020

                          Lead Product(s) : Perflutren,Immunoglobulin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 16, 2020

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          UNC Lineberger Comprehensive Cancer Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          UNC Lineberger Comprehensive Cancer Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 09, 2019

                          Lead Product(s) : Perflutren,Sulfur Hexafluoride Lipid Microspheres

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Lantheus Medical Imaging

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Definity

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 25, 2018

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 27, 2018

                          Lead Product(s) : Perflutren,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank